Standout Papers

Polatuzumab Vedotin in Re... 2019 2026 2021 2023 2019 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation benchmark for papers published in the same subfield and year, or reaches the top citation threshold in at least one of its specific research topics.

  1. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    2019 457 citations Laurie H. Sehn, Alex F. Herrera et al. Journal of Clinical Oncology

Immediate Impact

3 from Science/Nature 68 hit
Sub-graph 1 of 21

Citing Papers

Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia
2025 Hit
Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)
2025 Hit
15 intermediate papers

Works of Jamie Hirata being referenced

Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b–2 study
2019
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
2019 Hit
and 15 more

Author Peers

Author Last Decade Papers Cites
Jamie Hirata 1065 1036 417 224 215 64 1.4k
Roswitha Forstpointner 1464 1127 733 166 182 38 1.7k
Gerardo Musuraca 1212 557 521 296 342 83 1.7k
Cinzia Pellegrini 1112 518 294 231 317 84 1.4k
Andrew Haynes 1049 515 654 105 371 36 1.3k
Xiaonan Hong 925 1035 308 106 211 71 1.7k
Dirk Huebner 1351 1132 328 158 259 43 1.8k
Sandrine Roulland 1045 711 500 83 340 42 1.5k
Anne Lennard 829 559 562 56 239 51 1.6k
Clémentine Sarkozy 1026 782 368 43 203 73 1.4k
Manali Kamdar 808 1042 280 157 210 90 1.3k

All Works

Loading papers...

Rankless by CCL
2026